Physician profile
Nardine Assaad
NPI 1992830194
$1,680.97
in general payments reported to CMS, 2019-2025
17 companies · $380 in 2025
The $380 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $109 · 2021: $68.99 · 2022: $291 · 2023: $509 · 2024: $209 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $583.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $305.38 | 2019-2023 | Bexsero |
| Cranial Technologies, INC | $249.69 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $136.26 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $80.36 | 2022-2025 | |
| Corium, LLC | $48.89 | 2023 | Azstarys |
| Seqirus USA INC | $47.11 | 2021-2022 | |
| Neos Therapeutics, LP | $43.80 | 2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Aimmune Therapeutics, INC. | $29.12 | 2023 | |
| Phadia US INC. | $28.02 | 2022 | |
| Shire North American Group INC | $22.37 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.05 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $21.00 | 2023 | Methylphenidate Hydrochloride |
| Merck Sharp & Dohme LLC | $18.37 | 2025 | Rotateq, Enflonsia, Vaxneuvance |
| Vertical Pharmaceuticals, LLC | $17.11 | 2024 | Relexxii |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.97 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nardine Assaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.